Previous 10 | Next 10 |
2023-05-16 10:07:34 ET Gainers: Phio Pharmaceuticals ( PHIO ) +30% . Coya Therapeutics ( COYA ) +23% . Nanobiotix ( NBTX ) +12% . Savara ( SVRA ) +12% . Bellerophon Therapeutics ( BLPH ) +11% . Losers: Eloxx Pharmaceutical...
Calliditas Therapeutics: Interim Report Q1, 2023 PR Newswire STOCKHOLM , May 16, 2023 /PRNewswire/ -- Strong eGFR Data from Positive NefIgArd Phase 3 Trial Readout "In March we announced that the global NefIgArd Phase 3 trial successfully met its prim...
2023-04-27 09:17:35 ET Summary Part B portion of Phase 3 NefIgArd trial reveals positive outcomes for nefecon, leading to a reaffirmed buy recommendation for Calliditas. Nefecon demonstrates statistically significant stabilization of eGFR levels in IgAN patients, with consistent b...
Calliditas Therapeutics' 2022 Annual Report Published PR Newswire STOCKHOLM , April 26, 2023 /PRNewswire/ -- Calliditas Therapeutics AB (Nasdaq: CALT, Nasdaq Stockholm: CALTX) today announces that the Annual Report for 2022 now is available at the company's websi...
2023-04-12 06:34:14 ET Summary Calliditas Therapeutics recently reported positive long-term data of Tarpeyo (Nefecon/budesonide) in patients with IgA nephropathy. The results confirmed the previous positive findings from the phase 3 trial and indicate a potential disease-modifying...
NEW YORK, April 11, 2023 (GLOBE NEWSWIRE) -- Calliditas Therapeutics AB (Nasdaq: CALT, Nasdaq Stockholm: CALTX) (“Calliditas”), announced the publication of a cost-effective analysis of Nefecon (marketed in the United States as TARPEYO® (budesonide) delayed release capsules) ...
2023-04-06 05:40:50 ET Singapore's Health Sciences Authority (HSA) accepted to review Everest Medicines' application seeking approval of Nefecon to treat primary immunoglobulin A nephropathy (IgAN) in adults at risk of disease progression. The company expects to get approval of the...
Calliditas to participate in upcoming investor conferences PR Newswire STOCKHOLM , March 31, 2023 /PRNewswire/ -- Calliditas Therapeutics AB (Nasdaq: CALT, Nasdaq Stockholm: CALTX) ("Calliditas") today announced its management's participation in the following i...
2023-03-13 13:15:19 ET Calliditas Therapeutics ( NASDAQ: CALT ) added 35% on Monday after announcing that its Phase 3 trial for renal disease candidate Nefecon reached the primary endpoint, paving the way for Swedish pharma to seek its full approval. In Dec. 2021, the U....
2023-03-13 12:54:16 ET Gainers: Provention ( PRVB ) +258% . Euda Health ( EUDA ) +41% . Calliditas ( CALT ) +31% . Cipher Mining ( CIFR ) +29% . Caleminder ( CMND ) +26% . Bakkt ( BKKT ) +26% . Hut 8 Mining ( HU...
News, Short Squeeze, Breakout and More Instantly...
Calliditas Therapeutics AB Company Name:
CALT Stock Symbol:
NASDAQ Market:
Calliditas partner STADA receives European Commission decision for full approval of Kinpeygo® for the treatment of IgA Nephropathy PR Newswire STOCKHOLM , July 26, 2024 /PRNewswire/ -- Calliditas Therapeutics AB (Nasdaq: CALT, Nasdaq Stockholm: CALTX) ("Ca...
Calliditas announces positive TRANSFORM Phase 2b topline data in primary biliary cholangitis PR Newswire STOCKHOLM , July 26, 2024 /PRNewswire/ -- Calliditas Therapeutics AB (NASDAQ: CALT) ( STOCKHOLM : CALTX) ("Calliditas") today announced that the Pha...
Launch of Phase 3 clinical trial with Nefecon in Japan PR Newswire STOCKHOLM , July 4, 2024 /PRNewswire/ -- Calliditas Therapeutics AB (NASDAQ: CALT) (STO: CALTX) ("Calliditas") today announces that its partner Viatris Pharmaceutical Japan G.K. ("Viatri...